BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection
ATS Issues Guidance for Managing Postprematurity Respiratory Disease
Recommendations address the outpatient management of postprematurity respiratory disease in infants, children, and adolescents
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
Vaccinated Kidney Transplant Recipients Vulnerable to SARS-CoV-2 Variants
After two-dose vaccination, only 64 and 67 percent of kidney transplant recipients showed neutralization against B.1.351 (β) and B.1.617.2 (δ)
WMS Issues Guidelines on Tickborne Illness in the U.S.
Strong recommendations include the use of tick repellents for the skin (DEET, picaridin) and clothing (permethrin)
FDA Says Rapid At-Home COVID-19 Tests Not as Sensitive to Omicron
Agency says that antigen tests 'do detect the omicron variant, but may have reduced sensitivity'
No Effect on Ovarian Reserve Seen After mRNA COVID-19 Vaccination
Mean levels of anti-Müllerian hormone unchanged from baseline to three months after vaccination among reproductive-aged women
Guidance Offered for Managing Pain in Patients With Cancer and OUD
For patients with opioid use disorder taking buprenorphine-naloxone, it is deemed appropriate to continue three times-daily dosing
Dopamine Agonists, DRIs Similar for QoL in Parkinson Disease
No measurable difference in patient-rated quality of life seen for dopamine agonists versus dopamine reuptake inhibitors as adjuvant therapy
U.S. Adults Support Net-Risk Pediatric Research
Most support pediatric research posing minimal risk and research posing greater risk if it has high social value
